The Importance of Care Coordination for Patients with Psoriatic Arthritis


Joel M. Gelfand, MD, MSCE
Professor of Dermatology and Epidemiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
Vice Chair of Clinical Research
Medical Director, Dermatology Clinical Studies Unit
Director, Psoriasis and Phototherapy Treatment Center
Joel M. Gelfand, MD, MSCE

Joel M. Gelfand MD MSCE is Professor of Dermatology and Epidemiology (with tenure) at the University of Pennsylvania’s Perelman School of Medicine. He is also Vice Chair of Clinical Research, Medical Director of the Dermatology Clinical Studies Unit, and Director of the Psoriasis and Phototherapy Treatment Center. He is a nationally and internationally recognized expert in psoriasis, clinical epidemiology, drug safety, and clinical trials. Dr. Gelfand is the author of over 200 scientific publications, editorials, reviews, and text book chapters (cited over 16,600 times, H index 57) which appear in journals such as JAMA, BMJ, European Heart Journal, Annals of Rheumatic Disease, JAMA Dermatology, JAAD, and the JID. He is the recipient of the American Skin Association’s Psoriasis Achievement Award, PENN’s Marjorie Bowman Award, Penn’s Department of Biostatistics and Epidemiology’s epidemiology teaching award, NPF’s inaugural award for scientific achievement, and is an elected member of the American Society for Clinical Investigation.

He has given over 10 named lectureships and keynote addresses including the Society for Investigative Dermatology’s Eugene M. Farber lecture and the American Academy of Dermatology’s Marion B. Sulzberger lecture. He has received grant support from NIH, FDA, PCORI, the Dermatology Foundation, the American Skin Association, the National Psoriasis Foundation, and numerous pharmaceutical companies to support his independent research program. The overarching goal of his research and clinical practice is to improve psoriasis patient outcomes in the skin and joints, while lowering the risk of diabetes, CV disease and mortality.

Statement of Need

Psoriasis (PsO) and psoriatic arthritis (PsA) are complex disorders that require coordinated care between dermatologists and rheumatologists. Challenges to effective management include a lack of education of patients and health care providers (HCPs), suboptimal communication, and clinicians’ lack of a holistic treatment approach.

The third episode of this BriefCase series on challenging cases in PsO and PsA features a physician-patient office scenario video on educating the patient and strategies to coordinate care between specialists, as well as between specialists and primary care, with a goal of optimizing patient outcomes.

Learning Objectives

At the end of this CME/CE activity, participants should be able to coordinate care for patients with PsA to optimize outcomes and quality of life (QoL).

The following learning objectives pertain only to those requesting CNE or CPE credit: Summarize coordination of care for patients with PsA to optimize outcomes and QoL.

Financial Support

Supported by educational grants from Celgene and Novartis Pharmaceuticals Corporation.

Target Audience

Dermatologists, primary care physicians, nurse practitioners, physician assistants, and pharmacists

Credit Information

Physicians (ACCME) 1.0

CME Outfitters, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists/Pharmacy Tech (ACPE) 1.0

This application-based activity is approved for 1.0 contact hour (0.10 CEUs) of continuing pharmacy credit.
Activity UAN: 0376-0000-20-078-H01-P


Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Note to Nurse Practitioners

Nurse Practitioners can apply for AMA PRA Category 1 Credit through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit  from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Gelfand reports that he receives grants from AbbVie Inc.; Boehringer Ingelheim; Celgene Corporation; Janssen Biologics, Inc.; Novartis Corporation; Ortho Dermatologics; and Pfizer Inc. He is a consultant for Boehringer Ingelheim; Bristol-Myers Squibb Company; Janssen Biologics, Inc.; NeuroDerm Data and Safety Monitoring Board (DSMB); Novartis Corporation; Pfizer Inc.; Sun Pharmaceutical Industries; and UCB Data and Safety Monitoring Board (DSMB). He receives other financial or material support as a co-patent holder of resiquimod for treatment of cutaneous T-cell lymphoma; and as Deputy Editor for the Journal of Investigative Dermatology, receiving honoraria from the Society for Investigative Dermatology.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

  • Dr. Helfand (peer reviewer)
  • Mae Ochoa, RPh (peer reviewer)
  • Poshala Tish Aluwihare, PhD (planning committee)
  • Susan Perry (planning committee)
  • Jan Perez (planning committee)
  • Sharon Tordoff (planning committee)


CME Outfitters, LLC and the faculty do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Additional Formats

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.


NOTE: Pharmacist CE Universal Activity Number, Enduring: 0376-0000-20-078-H01-P.


Questions about this activity?

Call us at (877) CME-PROS or (877) 263-7767.


The Importance of Care Coordination for Patients with Psoriatic Arthritis
Event Date: 06/24/2020